Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | UBA1 | P22314 | 1/20 | 0.30 |
| ▸ | UBE2E1 | P51965 | 1/20 | 0.30 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1965402 | 0.92 | GSK3B (0.38) | GSK3BGSK3AMAPTKDM4ETDP1 | |
| SCHEMBL1119959 | 0.91 | GSK3B (0.35) | GSK3BGSK3AMAP3K12MAPTKDM4E | |
| SCHEMBL8000687 | 0.90 | GSK3B (0.37) | GSK3BGSK3AMAPTKDM4ETDP1 | |
| SCHEMBL8006538 | 0.90 | GSK3B (0.34) | GSK3BGSK3AMAPTACVR1MEN1 | |
| SCHEMBL1965614 | 0.90 | NOS3 (0.38) | GSK3BGSK3AMAPTKDM4ETDP1 | |
| SCHEMBL1119588 | 0.86 | GSK3B (0.49) | GSK3BGSK3A | |
| SCHEMBL1120237 | 0.84 | GSK3B (0.34) | GSK3BGSK3AACVR1 | |
| SCHEMBL12680879 | 0.81 | CNR1 (0.35) | GSK3BGSK3AMAPTKDM4ETDP1 | |
| SCHEMBL12680870 | 0.81 | KDM4E (0.36) | GSK3BGSK3AMAPTKDM4ETDP1 | |
| SCHEMBL12680861 | 0.80 | GSK3B (0.36) | GSK3BGSK3AMAPTKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280976-B1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AS GSK3BETA-INHIBITORS | BAYER IP GMBH (DE) | 2014-01-01 | — | — | EP | disclosed |
| EP-2280976-B1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AS GSK3BETA-INHIBITORS | BAYER IP GMBH (DE) | 2014-01-01 | — | — | EP | disclosed |
| US-20130296343-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-07 | — | — | US | disclosed |
| US-20130296343-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-07 | — | — | US | disclosed |
| US-8436003-B2 | Substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| US-20110144131-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | BAYER SCHERING PHARMA AKTIENGESELLESCHAFT (DE) | 2011-06-16 | — | — | US | disclosed |
| EP-2280976-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AS GSK3BETA-INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009138176-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AS GSK3BETA-INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296343-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | THPO, IKZF3, TPMT | GSK3B 3829/4885GSK3A 3600/4885MAP3K12 636/4885 |
| US-20110144131-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | THPO, IKZF3, TPMT | GSK3B 3829/4885GSK3A 3600/4885MAP3K12 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.